475 related articles for article (PubMed ID: 16239140)
1. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis.
Yokoyama A; Somervaille TC; Smith KS; Rozenblatt-Rosen O; Meyerson M; Cleary ML
Cell; 2005 Oct; 123(2):207-18. PubMed ID: 16239140
[TBL] [Abstract][Full Text] [Related]
2. Molecular basis of the mixed lineage leukemia-menin interaction: implications for targeting mixed lineage leukemias.
Grembecka J; Belcher AM; Hartley T; Cierpicki T
J Biol Chem; 2010 Dec; 285(52):40690-8. PubMed ID: 20961854
[TBL] [Abstract][Full Text] [Related]
3. A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin-MLL Inhibition.
Soto-Feliciano YM; Sánchez-Rivera FJ; Perner F; Barrows DW; Kastenhuber ER; Ho YJ; Carroll T; Xiong Y; Anand D; Soshnev AA; Gates L; Beytagh MC; Cheon D; Gu S; Liu XS; Krivtsov AV; Meneses M; de Stanchina E; Stone RM; Armstrong SA; Lowe SW; Allis CD
Cancer Discov; 2023 Jan; 13(1):146-169. PubMed ID: 36264143
[TBL] [Abstract][Full Text] [Related]
4. Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia.
Li BE; Ernst P
Exp Hematol; 2014 Dec; 42(12):995-1012. PubMed ID: 25264566
[TBL] [Abstract][Full Text] [Related]
5. HBO1-MLL interaction promotes AF4/ENL/P-TEFb-mediated leukemogenesis.
Takahashi S; Kanai A; Okuda H; Miyamoto R; Komata Y; Kawamura T; Matsui H; Inaba T; Takaori-Kondo A; Yokoyama A
Elife; 2021 Aug; 10():. PubMed ID: 34431785
[TBL] [Abstract][Full Text] [Related]
6. Property Focused Structure-Based Optimization of Small Molecule Inhibitors of the Protein-Protein Interaction between Menin and Mixed Lineage Leukemia (MLL).
Borkin D; Pollock J; Kempinska K; Purohit T; Li X; Wen B; Zhao T; Miao H; Shukla S; He M; Sun D; Cierpicki T; Grembecka J
J Med Chem; 2016 Feb; 59(3):892-913. PubMed ID: 26744767
[TBL] [Abstract][Full Text] [Related]
7. The PHD fingers of MLL block MLL fusion protein-mediated transformation.
Muntean AG; Giannola D; Udager AM; Hess JL
Blood; 2008 Dec; 112(12):4690-3. PubMed ID: 18796627
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel pyrrolo[2,3-d]pyrimidines as potent menin-mixed lineage leukemia interaction inhibitors.
Bai H; Yang Z; Lei H; Wu Y; Liu J; Yuan B; Ma M; Gao L; Zhang SQ; Xin M
Eur J Med Chem; 2024 Mar; 268():116226. PubMed ID: 38367493
[TBL] [Abstract][Full Text] [Related]
9. High-affinity small-molecule inhibitors of the menin-mixed lineage leukemia (MLL) interaction closely mimic a natural protein-protein interaction.
He S; Senter TJ; Pollock J; Han C; Upadhyay SK; Purohit T; Gogliotti RD; Lindsley CW; Cierpicki T; Stauffer SR; Grembecka J
J Med Chem; 2014 Feb; 57(4):1543-56. PubMed ID: 24472025
[TBL] [Abstract][Full Text] [Related]
10. MLL associates specifically with a subset of transcriptionally active target genes.
Milne TA; Dou Y; Martin ME; Brock HW; Roeder RG; Hess JL
Proc Natl Acad Sci U S A; 2005 Oct; 102(41):14765-70. PubMed ID: 16199523
[TBL] [Abstract][Full Text] [Related]
11. HOXA9 promotes MYC-mediated leukemogenesis by maintaining gene expression for multiple anti-apoptotic pathways.
Miyamoto R; Kanai A; Okuda H; Komata Y; Takahashi S; Matsui H; Inaba T; Yokoyama A
Elife; 2021 Jul; 10():. PubMed ID: 34310280
[TBL] [Abstract][Full Text] [Related]
12. MEN1 mutations mediate clinical resistance to menin inhibition.
Perner F; Stein EM; Wenge DV; Singh S; Kim J; Apazidis A; Rahnamoun H; Anand D; Marinaccio C; Hatton C; Wen Y; Stone RM; Schaller D; Mowla S; Xiao W; Gamlen HA; Stonestrom AJ; Persaud S; Ener E; Cutler JA; Doench JG; McGeehan GM; Volkamer A; Chodera JD; Nowak RP; Fischer ES; Levine RL; Armstrong SA; Cai SF
Nature; 2023 Mar; 615(7954):913-919. PubMed ID: 36922589
[TBL] [Abstract][Full Text] [Related]
13. Menin and Daxx Interact to Suppress Neuroendocrine Tumors through Epigenetic Control of the Membrane Metallo-Endopeptidase.
Feng Z; Wang L; Sun Y; Jiang Z; Domsic J; An C; Xing B; Tian J; Liu X; Metz DC; Yang X; Marmorstein R; Ma X; Hua X
Cancer Res; 2017 Jan; 77(2):401-411. PubMed ID: 27872097
[TBL] [Abstract][Full Text] [Related]
14. Combination of menin and kinase inhibitors as an effective treatment for leukemia with NUP98 translocations.
Miao H; Chen D; Ropa J; Purohit T; Kim E; Sulis ML; Ferrando A; Cierpicki T; Grembecka J
Leukemia; 2024 Jun; ():. PubMed ID: 38890447
[TBL] [Abstract][Full Text] [Related]
15. A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia.
Candoni A; Coppola G
Hematol Rep; 2024 Apr; 16(2):244-254. PubMed ID: 38651453
[TBL] [Abstract][Full Text] [Related]
16. The future of HOXA- expressing leukemias: Menin inhibitor response and resistance.
Wenge DV; Armstrong SA
Curr Opin Hematol; 2024 Mar; 31(2):64-70. PubMed ID: 38010951
[TBL] [Abstract][Full Text] [Related]
17. The mutational landscape of chromatin regulatory factors across 4,623 tumor samples.
Gonzalez-Perez A; Jene-Sanz A; Lopez-Bigas N
Genome Biol; 2013; 14(9):r106. PubMed ID: 24063517
[TBL] [Abstract][Full Text] [Related]
18. Editorial: Recent advances in diagnosis, prognosis, and therapy of oncogenic virus-driven tumors.
Tognon M; Martini F; Rotondo JC; Fiume G
Front Oncol; 2024; 14():1402877. PubMed ID: 38660129
[No Abstract] [Full Text] [Related]
19. Menin critically links MLL proteins with LEDGF on cancer-associated target genes.
Yokoyama A; Cleary ML
Cancer Cell; 2008 Jul; 14(1):36-46. PubMed ID: 18598942
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.
Borkin D; He S; Miao H; Kempinska K; Pollock J; Chase J; Purohit T; Malik B; Zhao T; Wang J; Wen B; Zong H; Jones M; Danet-Desnoyers G; Guzman ML; Talpaz M; Bixby DL; Sun D; Hess JL; Muntean AG; Maillard I; Cierpicki T; Grembecka J
Cancer Cell; 2015 Apr; 27(4):589-602. PubMed ID: 25817203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
